Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?. Can IBD Today [Internet]. 11 mai 2023 [cité 31 mars 2026];1(S05):2–7. Disponible à: https://canadianibdtoday.com/article/view/1-s05-ma